Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke

NCT04256473 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT04256473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04256473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke
Lead sponsor
Erasmus Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 10, 2019
Completion date
May 26, 2022
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke